B cell and B cell-related pathways for novel cancer treatments

Tokunaga, Ryuma; Naseem, Madiha; Lo, Jae Ho; Battaglin, Francesca; Soni, Shivani; Puccini, Alberto; Berger, Martin D.; Zhang, Wu; Baba, Hideo; Lenz, Heinz‐Josef

doi:10.1016/j.ctrv.2018.12.001

Cited by 166 publications

(151 citation statements)

References 99 publications

Supporting

Mentioning

132

Contrasting

Order By: Relevance

“…83 Upon binding of an antigen compatible with their specific receptor, and supported by cytokines released from Th cells, B cells can differentiate to plasma cells and produce antibodies specific to the antigen that triggered their differentiation. 84 However, B cells also act as antigen-presenting cells, promote differentiation of Th1 cells and Tcyt cells, and directly kill cancer cells through release of Granzyme B. 85 These functions support a tumoursuppressive role for B cells.…”

Section: Discussionmentioning

confidence: 99%

Tissue-infiltrating immune cells as prognostic markers in oral squamous cell carcinoma: a systematic review and meta-analysis

Hadler‐Olsen

Wirsing

2019

Br J Cancer

View full text Add to dashboard Cite

BACKGROUND: Various immune cells have been suggested as prognostic markers for cancer patients. In this article, we present a systematic review and meta-analysis of studies assessing the prognostic value of tissue-infiltrating immune cells in oral cancer and discuss the reporting quality of these studies. METHODS: We performed a systematic literature search and included studies using immunohistochemistry and survival analysis to assess the prognostic value of tumour-infiltrating T cells, B cells, macrophages, dendritic cells, mast cells and natural killer cells in oral cancer. We performed meta-analysis of studies providing necessary statistical data and investigated the studies' adherence to the REporting recommendations for tumour MARKer prognostic studies (REMARK) guidelines. RESULTS: Of the 1960 articles identified, 33 were eligible for this systematic review and 8 were included in the meta-analysis. CD163+ M2 macrophages and CD57+ natural killer cells were the most promising predictors of survival in oral cancer patients. Many studies lacked important information on their design and conduct. CONCLUSION: Deficiencies in the reporting of study design and conduct make it difficult to draw reliable conclusions about the suggested markers. The prognostic value of CD163+ M2 macrophages and CD57+ natural killer cells should be validated in large, standardised studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Tissue-infiltrating immune cells as prognostic markers in oral squamous cell carcinoma: a systematic review and meta-analysis

Hadler‐Olsen

Wirsing

2019

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Studies have shown that B lymphocytes can exert the above-mentioned tumor immune effects through the CCL19, 21/CCR7 axis, and CXCL13/CXCR5 axis, 167 but their specific effects in different cancer types and different stages have yet to be explored. In EC, studies have shown that infiltration of B cells and T cells in tumor tissues indicated a better prognosis.…”

Section: B Lymphocytesmentioning

confidence: 99%

<p>Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche</p>

Han¹,

Cao²,

Huang³

et al. 2020

CMAR

View full text Add to dashboard Cite

Esophageal cancer (EC) is the sixth most deadly cancer, and its incidence is still increasing year by year. Although the researches on the molecular mechanisms of EC have been widely carried out and incremental progress has been made, its overall survival rate is still low. There is cumulative evidence showing that the esophageal microenvironment plays a vital role in the development of EC. In precancerous lesions of the esophagus, high-risk environmental factors can promote the development of precancerous lesions by inducing the production of inflammatory factors and the recruitment of immune cells. In the tumor microenvironment, tumor-promoting cells can inhibit anti-tumor immunity and promote tumor progression through a variety of pathways, such as bone marrow-derived suppressor cells (MDSCs), tumor-associated fibroblasts (CAFs), and regulatory T cells (Tregs). The formation of extracellular hypoxia and acidic microenvironment and the change of extracellular matrix stiffness are also important factors affecting tumor progression and metastasis. Simultaneously, primary tumor-derived cytokines and bone marrow-derived immune cells can also promote the formation of pre-metastasis niche of EC lymph nodes, which are beneficial to EC lymph node metastasis. Further research on the specific mechanism of these processes in the occurrence, development, and metastasis of each EC subtype will support us to grasp the overall pre-cancerous prevention, targeted treatment, and metastatic assessment of EC.

show abstract

Section: Tumour Microenvironment (Tme) Of Solid Cancers Includingmentioning

confidence: 99%

“…B-cells have also been found as components of TILs within the TME of ovarian [ 108 ] and other cancers [ 109 ]. Like T-cells they contribute tumour suppressing, effector-cell subtypes; and immunosuppressive, regulatory B-cells (Bregs) [ 109 ]. Effector B-cells secrete antibodies, present antigen to T-cells and promote T-cell responses, and can directly kill cancer cells via granzyme B [ 109 ].…”

Section: Tumour Microenvironment (Tme) Of Solid Cancers Includingmentioning

confidence: 99%

“…Like T-cells they contribute tumour suppressing, effector-cell subtypes; and immunosuppressive, regulatory B-cells (Bregs) [ 109 ]. Effector B-cells secrete antibodies, present antigen to T-cells and promote T-cell responses, and can directly kill cancer cells via granzyme B [ 109 ]. Bregs, producing IL-10, and expressing high levels of CD80 and CD86, also contribute to the maintenance of tolerance and immunosuppression.…”

Section: Tumour Microenvironment (Tme) Of Solid Cancers Includingmentioning

confidence: 99%

See 1 more Smart Citation

Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

Macpherson

Barry

Ricciardelli

et al. 2020

JCM

View full text Add to dashboard Cite

Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, most patients receive little or no benefit from immunotherapy, which has been attributed to the tumour microenvironment and immune evasion. Although the US Food and Drug Administration have approved immunotherapies for some cancers, to date, only the anti-angiogenic antibody bevacizumab is approved for the treatment of epithelial ovarian cancer. Immunotherapeutic strategies for ovarian cancer are still under development and being tested in numerous clinical trials. A detailed understanding of the interactions between cancer and the immune system is vital for optimisation of immunotherapies either alone or when combined with chemotherapy and other therapies. This article, in two main parts, provides an overview of: (1) components of the normal immune system and current knowledge regarding tumour immunology, biology and their interactions; (2) strategies, and targets, together with challenges and potential innovative approaches for cancer immunotherapy, with attention given to epithelial ovarian cancer.

show abstract

B cell and B cell-related pathways for novel cancer treatments

Cited by 166 publications

References 99 publications

Tissue-infiltrating immune cells as prognostic markers in oral squamous cell carcinoma: a systematic review and meta-analysis

Tissue-infiltrating immune cells as prognostic markers in oral squamous cell carcinoma: a systematic review and meta-analysis

<p>Esophageal Microenvironment: From Precursor Microenvironment to Premetastatic Niche</p>

Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

Contact Info

Product

Resources

About